Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392
株式のランク
#3624
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical... Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.
株価
$3.71
最終同期: 2026-10-20
時価総額
$4.69B
変化（1日）
2.44%
変化（1年）
-52.25%
国
CN
取引 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
カテゴリー
Healthcare
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.（603392）の利益
Jun 2026 時点の利益 TTM: $-68.50M
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. の最新の財務報告によると、同社の現在の利益は $-68.50M です。2023 年には $196.85M の利益を上げ、これは 2022 年の利益 $809.33M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. の利益の推移（2013 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-68.50M | -840.89% |
| 2024 | $9.25M | -95.30% |
| 2023 | $196.85M | -75.68% |
| 2022 | $809.33M | 121.33% |
| 2021 | $365.67M | 212.48% |
| 2020 | $117.02M | 275.84% |
| 2019 | $31.14M | -26.22% |
| 2018 | $42.20M | 53.78% |
| 2017 | $27.44M | 24.77% |
| 2016 | $21.99M | 8.94% |
| 2015 | $20.19M | -6.87% |
| 2014 | $21.68M | 27.42% |
| 2013 | $17.01M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -7,801.05% |
US
|
|
| $-3.09B | 4,406.84% |
US
|
|
| $-4.02B | 5,763.42% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,947.84% |
NL
|
